🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In @targetedonc: A retrospective study presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research meeting demonstrated a decade-long surge in biomarker testing for metastatic bladder cancer. Click to read the article: targetedonc.com/view/biomarker…

Maintenance therapy with oral selinexor extended PFS in patients with TP53 wild-type advanced or recurrent endometrial cancer, according to new data from the phase 3 SIENDO trial. #SGO25 | Debra Richardson, M.D. OU Health Stephenson Cancer Center hubs.li/Q03nFj9V0

Experts discuss how prophylaxis against opportunistic infections is essential for patients on immunosuppressive therapy for #cGVHD. Catherine Lee Fred Hutch Cancer Center Paul Shaughnessy Methodist Physicians hubs.li/Q03nkVXL0

A study presented during the #ASCO25 press briefing found, in an analysis of more than 170,000 patients, that GLP-1 drugs were not associated with higher cancer rates, and actually led to a decrease in obesity-related cancers and deaths. hubs.li/Q03nXCSf0

The first patient has been dosed with mRNA-4106, a novel pantumor antigen therapy candidate, in a phase 1 trial for those with advanced or metastatic solid tumors. Amita Patnaik Moderna hubs.li/Q03n8fcj0

Inavolisib + palbociclib + fulvestrant demonstrated a statistically significant improvement in OS in patients with PIK3CA-mutant, HR+, HER2-, endocrine-resistant advanced breast cancer, according to the final OS analysis of the INAVO120 trial. #ASCO25 hubs.li/Q03nXNf90

AI-assisted training bettered pathologist concordance and reduced misclassification in HER2-low and HER2-ultralow breast cancer, highlighting the value of AI systems in biomarker interpretation training. #ASCO25 #bcsm hubs.li/Q03nYLyH0

Big news from the May 21 #ASCO25 press briefing: 🔹 GLP-1s show cancer risk reduction 🔹 AI boosts HER2-low scoring accuracy 🔹 Inavolisib triplet extends survival in PIK3CA-mutant breast cancer 🔹 Lurbinectedin combo shows OS/PFS gains in SCLC hubs.li/Q03n-sy20

WATCH: John L. Marshall, MD, discusses unmet needs in the targeted therapy space and the importance of optimizing dosing in colorectal cancer. #crcsm hubs.li/Q03nGgcK0

Frontline maintenance therapy with lurbinectedin and atezolizumab bettered PFS and OS when compared with atezolizumab alone in patients with ES-SCLC, according to primary findings from the phase 3 IMforte trial. #lcsm #ASCO25 hubs.li/Q03nYXbv0

Discover the inside scoop on the impact of the FDA's landmark ODAC vote on MRD as an end point in myeloma trials, the future of MRD research, and more in our exclusive interview with C. Ola Landgren, M.D. from Sylvester Comprehensive Cancer Center. Unlock the full insights here: hubs.li/Q03nRV5R0

Dermatological Complications of JAK Inhibitors: Monitoring and Management #mpnsm | Duke Health Duke Cancer Andrew Kuykendall MD Moffitt Cancer Center hubs.li/Q03nkZSj0

In this video, Deepak Bhamidipati, MD, discusses the impact of the FDA's Project Optimus on early-phase drug development protocols. Sarah Cannon Docs hubs.li/Q03nGdCY0

Sarah A. Holstein, MD, PhD, (University of Nebraska Medical Center) and Shashank Cingam, MD, (Shashank Cingam of UNM Comprehensive Cancer Center) discuss options for a patient with relapsed/refractory multiple myeloma and the use of CAR T-cell therapy. #mmsm hubs.li/Q03n8kfX0

The countdown to #ASCO25 is on! Get ready for practice-changing breakthroughs in immunotherapy, targeted therapies, ADCs & more. 👉Read the preview: hubs.li/Q03n-vKy0 Manmeet Ahluwalia, MD, MBA, FASCO Baptist Health City of Hope MGH Breast Oncology Sara Tolaney Dana-Farber’s Breast Oncology Center AHN Alan Tan

May is #BrainCancerAwarenessMonth and Manmeet Ahluwalia, MD, MBA, FASCO, discussed its importance for a community oncologist audience. Read more: hubs.li/Q03nFnW80 Manmeet Ahluwalia, MD, MBA, FASCO Baptist Health

Anuradha Krishnamurthy, MBBS, provides backgrounds on TILs and discusses their critical role in the advanced melanoma treatment landscape. #melanoma #melsm hubs.li/Q03nG6KY0

Cohort 1 of the phase 1 dose-escalation trial of GTB-3650, a second-generation TriKE, for the treatment of patients with relapsed/refractory CD33+ hematologic malignancies has successfully been completed. hubs.li/Q03nSbL40

Long-term follow-up data from a phase 3 trial has reaffirmed that early rituximab monotherapy delays the need for new treatment in patients with advanced-stage, asymptomatic, low tumor burden follicular lymphoma. #lymsm hubs.li/Q03nS5160